Conferences - Results from #9660

EAU 2017: Special session of the Prostate Cancer Prevention Group: PLCO March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group: ERSPC March 25, 2017

EAU 2017: Special session of the Prostate Cancer Prevention Group: ProtecT March 25, 2017

EAU 2017: Multimodal bladder preservation technique for muscle invasive bladder cancer: Results from a prospective trial March 25, 2017

EAU 2017: Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial March 25, 2017

EAU 2017: Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder March 25, 2017

EAU 2017: Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052 March 24, 2017

EAU 2017: 4th ESO Prostate Cancer Observatory: The Urologist’s Perspective on Active Surveillance March 24, 2017

EAU 2017: 4th ESO Prostate Cancer Observatory: The Imaging Specialist’s Perspective on MRI March 24, 2017

EAU 2017: 4th ESO Prostate Cancer Observatory: The Pathologist’s Perspective March 24, 2017

EAU 2017: 4th ESO Prostate Cancer Observatory: The Radiation Oncologist’s Perspective March 24, 2017

EAU 2017: 4th ESO Prostate Cancer Observatory: The Medical Oncologist’s Perspective March 24, 2017

EAU 2017: 4th ESO Prostate Cancer Observatory: The Imaging Specialist’s Perspective on PSMA March 24, 2017

EAU 2017: What is the optimal post-operative management of men with lymph node recurrent prostate cancer after salvage lymph node dissection? Results from a large, multi-institutional series March 24, 2017

Cytoreductive Radical Prostatectomy cRP in men with hormone-naive, metastatic prostate cancer (mPCA) | EAU 2017: March 24, 2017

EAU 2017: Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP) March 24, 2017

EAU 2017: Predictors of early cancer specific and other cause mortality in high risk prostate cancer patients after radical prostatectomy: Results from a large, multi-institutional analysis March 24, 2017

EAU 2017: Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial March 24, 2017

EAU 2017: Extended pelvic lymph node dissection for intermediate-high risk prostate cancer: Frequency and distribution of nodal metastases March 24, 2017

EAU 2017: Freedom from androgen deprivation and radiotherapy therapy after upfront minimally invasive surgery for high-risk prostate cancers March 24, 2017

Page 484 of 589